Stay away from heartache! Hematopoietic stem cells for angina pectoris

The research team of Northwestern University and Northwestern Memorial Hospital in Chicago recently published the results of the second phase clinical trial of chronic angina pectoris: injecting CD34+ hematopoietic stem cells into the damaged part of the heart can effectively slow down the degree of myocardial necrosis of angina pectoris after half a year, and continuously enhance the exercise ability of patients and relieve the degree of chest tightness. The findings have been published in the online journal of the American Heart Association.

In the lab.-the blood bag in the tin box. (Photo courtesy/Shengbao Cord Blood Bank) The subjects of this experiment were 167 patients with angina pectoris, and 65438+ 10,000 autologous bone marrow hematopoietic stem cells were injected per kilogram for treatment, with a total of 10 myocardial necrosis areas. Hematopoietic stem cells can promote hematopoiesis and angiogenesis, so they can reduce myocardial hypoxia. After six months, the degree of injury decreased from 10.9 to 6.8, and the exercise tolerance of patients continued to increase. No matter walking or standing up, there is no obvious chest pain.

In the past, angina pectoris relied on vascular bypass surgery or drug treatment. Previous studies on stem cells were mostly aimed at acute angina pectoris and treated with cardiac precursor cells. The effect of this clinical trial using hematopoietic stem cells is more significant and continues to improve.

Get healthy and high! ""fan group!